Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.800 +0.100 (+2.70%)
Delayed Quote Updated: 2:53 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Wednesday's session: gap up and gap down stocks ↗
Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Nasdaq Gains Over 100 Points; Dollar Tree Post Upbeat Earnings ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Wednesday? ↗
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Insights into WAVE Life Sciences's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 6 Analysts Discuss WAVE Life Sciences Stock ↗
 
Via Benzinga
News headline image
Wave (WVE) Q2 Revenue Drops 56% ↗
Via The Motley Fool
News headline image
WAVE Life Sciences Earnings Preview ↗
 
Via Benzinga
News headline image
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shares ↗
Wave Life Sciences Q2 2025 results show $8.7M revenue miss but narrower EPS loss. Stock rises on optimism for WVE-006's AATD clinical progress. 
Via Chartmill
News headline image
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Where WAVE Life Sciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave’s robust RNA medicines pipeline 
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year ↗
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements. 
Via Benzinga
News headline image
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 4, 2025 ↗
 
Via Benzinga
News headline image
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.